Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure

Stefan Porubsky,1,2* Giuseppina Federico,1 Johannes Müthing,1 Richard Jennemann,1 Norbert Gretz,3 Stefan Böttner,3 Nicholas Obermüller,3 Oliver Jung,5 Ingeborg A Hauser,5 Elisabeth Gröne,1 Helmut Geiger,1 Hermann-Josef Gröne1 and Christoph Betz5

1 Department of Cellular and Molecular Pathology, German Cancer Research Centre, Heidelberg, Germany
2 Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany
3 Institute for Hygiene, University of Münster, Germany
4 Medical Research Centre, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany
5 Department of Nephrology, University Hospital Frankfurt-am-Main, University of Frankfurt, Germany

*Correspondence to: S Porubsky, Department of Cellular and Molecular Pathology, German Cancer Research Centre, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. E-mail: s.porubsky@dkfz.de

Abstract
The pathogenesis and therapy of Shigatoxin 2 (Stx2)-mediated kidney failure remain controversial. Our aim was to test whether, during an infection with Stx2-producing E. coli (STEC), Stx2 exerts direct effects on renal tubular epithelium and thereby possibly contributes to acute renal failure. Mice represent a suitable model because they, like humans, express the Stx2 receptor Gb3 in the tubular epithelium but, in contrast to humans, not in glomerular endothelia, and are thus free of glomerular thrombotic microangiopathy (TMA). In wild-type mice, Stx2 caused acute tubular dysfunction with consequent electrolyte disturbance, which was most likely the cause of death. Tubule-specific depletion of Gb3 protected the mice from acute renal failure. In vitro, Stx2 induced secretion of proinflammatory cytokines and apoptosis in human tubular epithelial cells, thus implicating a direct effect of Stx2 on the tubular epithelium. To correlate these results to human disease, kidney biopsies and outcome were analysed in patients with Stx2-associated kidney failure (n = 11, aged 22–44 years). The majority of kidney biopsies showed different stages of an ongoing TMA; however, no glomerular complement activation could be demonstrated. All biopsies, including those without TMA, showed severe acute tubular damage. Due to these findings, patients were treated with supportive therapy without complement-inhibiting antibodies (eculizumab) or immunoadsorption. Despite the severity of the initial disease [creatine 6.34 (1.31–17.60) mg/dl, lactate dehydrogenase 1944 (753–2792) IU/l, platelets 33 (19–124)]/nl and haemoglobin 6.2 (5.2–7.8) g/dl; median (range)], all patients were discharged after 33 (range 19–43) days with no neurological symptoms and no dialysis requirement [creatinine 1.39 (range 0.84–2.86) mg/dl]. The creatinine decreased further to 0.90 (range 0.66–1.27) mg/dl after 24 months. Based on these data, one may surmise that acute tubular damage represents a separate pathophysiological mechanism, importantly contributing to Stx2-mediated acute kidney failure. Specifically in young adults, an excellent outcome can be achieved by supportive therapy only.

Keywords: acute renal failure; acute tubular damage; electron microscopy; globoside (Gb3, CD77); Shigatoxin; Shigatoxin-producing Escherichia coli (STEC); thrombotic microangiopathy

Received 7 January 2014; Revised 29 May 2014; Accepted 4 June 2014

No conflicts of interest were declared.

Introduction

In 1983, E. coli O157:H7 was recognized as a human pathogen inducing haemorrhagic colitis [1]. Subsequently, an association between post-diarrhoeal haemolytic uraemic syndrome (HUS) and the production of Shigatoxin 2 (Stx2) was established [2], and Stx2-producing E. coli (STEC) continuously attract attention in association with repetitive outbreaks of food-borne illnesses throughout the world [3,4] (reviewed in [5–7]). In 2011, an epidemic of STEC spread through Germany; 3816 cases of acute gastroenteritis, 845 cases of HUS and 54 deaths were attributed to the infection [8]; predominantly young adult females were affected [8]. Stool contained the unusual E. coli strain O104:H4 with characteristics of STEC and enterohaggregative E. coli [9–11].

The pathogenetic sequence of STEC-associated human disease is unknown. The toxin accesses the circulation during colitis. Globotrihexosylceramide (Gb3 or CD77) functions as the cellular Stx2 receptor [12]. Stx2–Gb3 interaction leads to Stx2 internalization and retrograde transport to the endoplasmic reticulum, where it irreversibly inactivates ribosomes and...
interferes with proteosynthesis [7]. In addition, effects on intracellular signalling, increased production of proinflammatory cytokines and physicochemical modes of Stx2 action on plasma membrane, including bending of the membrane lipid bilayer and perturbation of lipid clustering, have been discussed [13–16].

The clinical manifestations are variable [17]. Acute neurological complications develop in about 25% of patients [18]. The majority of patients show acute renal failure, but its development is not correlated to the degree of haemolysis and thrombocytopenia, which warrant the diagnosis of HUS [18,19]. In the German 2011 epidemic, 22% of patients with acute enteritis met the criteria for HUS [8]. These data suggest that kidney failure is not necessarily linked to thrombotic microangiopathy (TMA) and haemolysis. Thus, other mechanisms inducing kidney failure may play a role during infection with STEC.

The appropriate management of STEC infections remains a challenge [20]. Recently, eculizumab, a humanized monoclonal antibody neutralizing complement factor C5, has been implemented for the treatment of paroxysmal nocturnal haemoglobinuria and atypical (ie STEC-unrelated) HUS [21–23]. Early during the outbreak of the 2011 epidemic, a successful therapy in three children with STEC-related HUS was reported [24]. In response, eculizumab was tested as a ‘rescue therapy’ in over 300 patients. However, analyses of the clinical data have been unable to demonstrate significant benefits of this treatment [25,26].

Our goal in this report was to obtain an insight into the processes involved in the kidney failure elicited by STEC; we investigated Stx2 effects in vivo on murine models and in vitro on tubular epithelial cells.

Materials and methods

Histology

The review board of the Goethe-University Hospital in Frankfurt am Main, Germany, approved the analysis of the patient data. Tissue samples were fixed in 4% phosphate-buffered paraformaldehyde, paraffin-embedded and subjected to routine diagnostic procedures: periodic acid–Schiff (PAS) and Goldner’s trichrome staining, immunohistochemistry for IgA, IgG, IgM, C1q, C3, fibrin/fibrinogen (Dako, Hamburg, Germany) and electron microscopy (see also supplementary material, Supplementary materials and methods). The alkaline phosphatase/anti-alkaline phosphatase (APAAP) and avidin-biotinylated enzyme complex (ABC) methods were performed as described [27]. Chloracetate esterase (CAE) staining was performed as described [28]. For Gb3 immunohistochemistry, formalin-fixed tissue was incubated in 30% sucrose overnight and stored at −80°C; cryosections were probed with polyclonal chicken anti-Gb3 antibody JMO6/298-1 [29], followed by alkaline phosphatase-conjugated polyclonal donkey anti-IgY secondary antibody (Jackson ImmunoResearch Europe, Suffolk, UK). Sections were scanned using a confocal laser microscope (TCS-SL, Leica, Wetzlar, Germany).

Glomerular TMA was semi-quantified on a PAS-stained slide by scoring the extent of TMA in each glomerulus as: 0, absent; 0.5, present in one-quarter of the glomerulus; 1, present in one-half; 2, present in three-quarters; and 3, encompassing the whole glomerulus. The percentage representation of each score was calculated. The total score was built by adding these percentages, multiplied by the corresponding score (eg a case with 100% globally thrombosed glomeruli would reach the maximum score of 300).

Similarly, the acute tubular damage was assessed: Cortical tubular epithelial cells were first separately evaluated for the extent of: (a) brush border loss in proximal tubules; (b) epithelial cell flattening; and (c) vacuolization. Each phenomenon was separately scored as: 0, absent; 0.5, discretely present; 1, slightly present; 2, moderately present; and 3, severely present. In analogy to the evaluation of glomeruli, here the score for each of the three parameters was also calculated as the sum of the percentage representation of each score, multiplied by the score itself (ie leading to values in the range 0–300). The acute tubular damage of each case was expressed by adding the scores for brush border loss, epithelial cell flattening and vacuolization (ie leading to values in the range 0–900).

For evaluation of the immunohistochemistry for β-catenin and CD44, the staining was scored on tubular cells in each high-power field (HPF) as: 0, no staining detectable; 1, faint staining; 2, moderate staining; and 3, intense staining. The staining score was calculated by adding all staining intensities multiplied by the percentage of fields, showing the respective staining intensity. In case of the immunohistochemistry for Ki67 and cleaved caspase 3, the number of positive tubular cells was expressed as average cell number/HPF (x400 magnification). In case of the immunohistochemistry for CD3 and CD68 and CAE staining, the number of positive cortical interstitial cells was expressed as average cell number/HPF.

For electron microscopy, tissue was post-fixed in Karnovsky’s glutaraldehyde (2% paraformaldehyde, 2.5% glutaraldehyde and 0.2 M cacodylate buffer, pH 7.4) and embedded in araldite (Serva Electrophoresis, Heidelberg, Germany). Ultrathin sections were stained with lead citrate and uranyl acetate. Electron micrographs were taken on a Zeiss EM 910 electron microscope (Carl Zeiss, Oberkochen, Germany).

Animal models

Gb3S−/− (A4galttm1.1Poru) and Ugcgfl/fl (Ugcgtm1.1Hjg) mice were generated by our group [30,31]. Pax8cre, Ptf4cre and Tie2cre have been reported previously [32–34]. As all strains were backcrossed to the C57BL/6 genetic background for >10 generations, we used C57BL/6 mice as wild-type controls. For induction of Cre activity in the Tie2cre strain, mice...
Figure 1. Legend on next page
were injected with 1 mg tamoxifen (Sigma, Schnelldorf, Germany) in 200 μl sunflower oil on five consecutive days. Eight week-old mice were injected intraperitoneally (i.p.) with 0.2 μg Stx2 (Nacalai Tesque, Kyoto, Japan) dissolved in 200 μl PBS. Measurement of the endotoxin concentration in the Stx2 stock solution was performed by Mikrobiologisches Labor (Münster, Germany). The amount of LPS co-administered with one Stx2 dose was 1.32 × 10^{-3} endotoxin units (EU)/mouse (0.066 EU/kg body weight), which corresponds approximately to 0.132 pg LPS/mouse. In the case of LPS injection, mice were injected i.p. with 40 μg LPS from E. coli 0111:B4 (Sigma).

Urine was collected in metabolic cages with water access ad libitum. Urine and blood were analysed on a Hitachi 9-17E analyser (Hitachi Chemical, Düsseldorf, Germany). Animal experiments were approved by the institutional board and the corresponding local authority.

**Results**

In mice, Shigatoxin 2 caused a direct toxic effect on renal tubular epithelium with consequent acute renal failure

Mice represented a suitable model to analyse the TMA-unrelated effects of Stx2 on kidney cells in vivo, because they, in contrast to humans, do not express the Stx2 receptor Gb3 on renal endothelial cells, under either native or LPS-stimulated conditions (Figure 1A; see also supplementary material, Figure S1). As visualized by a complete co-localization with aquaporin 2, the expression of Gb3 was restricted to collecting ducts in the murine kidney (see supplementary material, Figure S2).

After i.p. injection of 0.2 μg Stx2, WT mice died between days 2 and 4 (Figure 1B). In contrast, all Gb3-deficient mice survived the Stx2 injection without any deterioration of their general status or histological abnormalities. Consistent with the absence of Gb3 in the murine glomerulus and renal blood vessels, TMA was not observed in moribund WT mice 36 h after the Stx2 injection (Figure 1C). In line with this, these mice did not show any elevation of serum LDH or any decrease in platelets (Figure 1B). Similarly, no depositions of complement factor C3 were detected in glomeruli and renal blood vessels upon Stx2 administration (see supplementary material, Figure S3). Despite this, Stx2-injected WT mice showed a significant (p < 0.01) increase in serum creatinine (PBS-injected WT 0.12 ± 0.006 mg/dl, versus Stx2-injected WT 0.22 ± 0.024 mg/dl; mean ± SEM, n = 14 and n = 8, respectively) and significant hyponatraemia and hyperkalaemia (Figure 1F). These changes were accompanied by an elevated sodium concentration as well as a decreased potassium concentration in the urine, thus indicating profound renal tubular dysfunction. The serum electrolyte dysregulation and not TMA was therefore the likely cause of death in the WT mice.

To verify that Stx2 toxicity towards the tubular epithelium is causative in the development of these changes,
we used a mouse with tubule-specific Gb3 deficiency. To this end, we crossed the *Ugcg*<sup>fl/fl</sup> mouse to a strain with tubule-specific Cre activity (*Pax8<sup>cre</sup>*) thereby eliminating the synthesis of glycosphingolipids two steps upstream from Gb3 synthase (Figure 1D, E). Similar to the mice with a global Gb3 deficiency, the mice with a tubule-specific Gb3 deficiency (*Pax8<sup>cre</sup>/Ugcg<sup>fl/fl</sup>*) were fully protected from the toxic effects of Stx2 towards the renal epithelium (Figure 1F), further strengthening the notion that the tubular damage was causative in mediating the lethal Stx2 effects.

Although *Pax8<sup>cre</sup>/Ugcg<sup>fl/fl</sup>* mice survived the first 4 days after the Stx2 injection and did not show either renal failure or blood and urine electrolyte disturbances, severe neurological effects developed, starting at day 4 after the Stx2 injection (Figure 2A). The mice showed neurological symptoms with general weakness, abnormal gait, tremor and seizures, and 50% of them died during the next 4 days. Autopsy demonstrated a diffuse cerebral purpura (Figure 2B, C) resembling human thrombotic thrombocytopenic purpura (Moschcowitz syndrome).

Considering that platelets [37] and murine cerebral endothelium [38] express Gb3 and thus come into question as potential initiators of the observed cerebral thrombosis, we tested whether an additional depletion of Gb3 in platelets or endothelial cells would alleviate the cerebral purpura. For this purpose, *Pax8<sup>cre</sup>/Ugcg<sup>fl/fl</sup>* mice were crossed with a strain expressing Cre in either platelets (*PF4<sup>cre</sup>*) or endothelial cells (*Tie2<sup>cre</sup>*). The additional depletion of Gb3 in platelets (*Pax8<sup>cre</sup>/PF4<sup>cre</sup>/Ugcg<sup>fl/fl</sup>*) did not ameliorate the cerebral purpura and did not improve the survival of animals (Figure 2D). However, introducing the inducible endothelial-specific Gb3 deficiency in

![Figure 2](image-url)

**Figure 2.** Mice lacking the Stx2-receptor Gb3 in tubular epithelium developed cerebral purpura after Stx2-injection. (A) Although *Pax8<sup>cre</sup>/Ugcg<sup>fl/fl</sup>* mice were protected from kidney failure and electrolyte dysregulation (shown in Figure 1F), severe and partially fatal neurological symptoms occurred 4–8 days after the Stx2 injection. (B, C) Autopsy revealed diffuse cerebral purpura (B) with bleeding and cerebral TMA; Goldner's trichrome staining, visualizing red blood cells in the haemorrhage foci; magnification ×200. (D) Depletion of Gb3 in endothelial cells in addition to the tubular cells (*Pax8<sup>cre</sup>/Tie2<sup>cre</sup>/Ugcg<sup>fl/fl</sup>*, green line) conferred a partial protection from cerebral purpura and improved survival significantly as compared to pure tubular depletion of Gb3 (*Pax8<sup>cre</sup>/Ugcg<sup>fl/fl</sup>*, blue line). In contrast, depletion of Gb3 in platelets in addition to tubular cells (*Pax8<sup>cre</sup>/PF4<sup>cre</sup>/Ugcg<sup>fl/fl</sup>*, yellow line) did not prove to be protective. As expected, mice with Gb3 deficiency solely in platelets or endothelial cells (*PF4<sup>cre</sup>/Ugcg<sup>fl/fl</sup> and *Tie2<sup>cre</sup>/Ugcg<sup>fl/fl</sup>*, respectively) died during the early phase, contemporarily with the Stx2-exposed WT mice.
PAX8cre/Tie2cre/Ugcgfl/fl mice ameliorated the cerebral purpura and significantly improved survival (Figure 2D).

Investigations of STEC-infected patients

We studied the disease course and kidney biopsies in patients with STEC infection at the University Hospital in Frankfurt am Main, Germany (Table 1). All cases (nine females and two males) were admitted during the German 2011 epidemic during 12–28 May 2011 and presented with diarrhoea. The median time between diarrhoea onset and the initial admission was 4 (range 0–10) days. Upon the initial admission, median creatinine was 0.84 (range 0.48–17.60) mg/dl, platelet count 216 (range 35–380) × 10⁹/l, haemoglobin 13.8 (range 5.8–17.7) g/dl and LDH 278 (range 175–1994) U/l. Stx2-producing E. coli O104:H4 was detected in the stools of eight patients. All patients showed neurological symptoms, such as headache (n = 3), cognitive defects (n = 10), aphasia (n = 1), paresis (n = 2), seizures (n = 3) and coma (n = 1). During the following days, platelet count decreased to 33 × 10⁹/l, haemoglobin to 6.2 g/dl, LDH rose to 1944 U/l and creatinine to 6.34 mg/dl, corresponding to an estimated glomerular filtration rate (eGFR) of 8.5 ml/min/1.73 m² (Table 1). The patients showed slightly decreased levels of complement factor C3 (average of the lowest C3 level 71 mg/dl; normal values 90–180 mg/dl) and complement C4 levels in the lower normal range (average of the lowest C4 level 11 mg/dl; normal values 10–40 mg/dl).

Therapy and outcome

All patients received supportive therapy (Table 1). Nine patients required haemodialysis for a mean time period of 18.5 days. All 11 patients received red blood cell transfusion and in 10 plasmapheresis was performed because of an elevation of LDH > 800 U/l and/or severe neurological symptoms, such as seizures, paresis or coma. In three patients, mechanical ventilation was necessary. Supportive treatment did not include antibiotic therapy primarily. However, during the hospital stay, eight patients received antibiotics because of suspected nosocomial infection. None of the patients were treated with eculizumab or immunoadsorption.

The patients were discharged after a median period of 33 days with no dialysis requirement and no neurological symptoms. Upon discharge, the median creatinine was 1.39 mg/dl. A 2 year follow-up showed stable kidney function with creatinine levels of 0.92, 0.91 and 0.90 mg/dl, 6, 12 and 24 months, respectively, after discharge.

Table 1. Clinical parameters in comparison to other cohorts treated with eculizumab or immunoadsorption during the 2011 German epidemic

| Patient characteristics | Frankfurt cohort | Kielstein et al [25] | Menne et al [26] | Greinacher et al [53] |
|-------------------------|------------------|---------------------|------------------|----------------------|
| n                       | 11               | 193                 | 67               | 12                   |
| Age (years)             | 30 (#22–44)      | 45                  | 50.6             | 51                   |
| Gender (females, %)     | 9 (82)           | 146 (75.6)          | 56 (84)          | 11 (82)              |
| Creatinine, highest (mg/dl) | 6.34 (#1.3–17.6) | 4.9                | 2.55             | n.r.                 |
| Platelets, lowest (10⁹/l) | 33 (#19–124)    | 30                 | 57.6             | 38                   |
| Haemoglobin, lowest (g/dl) | 6.2 (#5.2–7.8)  | 6.3                | 11.6             | n.r.                 |
| LDH, highest (U/l)      | 1944 (#753–2792) | 1437               | 1160             | 1500                 |
| Severe neurological symptoms* (n, %) | 4 (36.4) | 76 (39.4) | 16 (24) | 6 (50) |
| Therapy                 |                  |                     |                  |                      |
| Mechanical ventilation (n, %) | 3 (27.3)      | 67 (34.7)           | 23 (34)          | 9 (75)               |
| Red blood cell transfusion (n, %) | 11 (100)    | 103 (53.4)          | n.r.             | n.r.                 |
| Dialysis requirement (n, %) | 9 (82)        | 145 (75.1)          | 51 (76.1)        | 10 (83)              |
| Dialysis duration (days) | 18.5 (#4–28)   | n.r.                | n.r.             | 18.3                 |
| Eculizumab administration (n, %) | 0            | 193 (100)           | 67 (100)         | 8 (67)               |
| Immunoabsorption (n, %)  | 0               | 0                   | 12 (100)         |                      |
| Plasmapheresis (n, %)    | 10 (91)         | 193 (100)           | 66 (98.5)        | 10 (83)              |
| Outcome                 |                  |                     |                  |                      |
| Hospital stay duration (days) | 33 (#19–40)  | 27                  | 31.2             | n.r.                 |
| Overall mortality (n, %) | 0               | 5 (2.6)             | 3 (5)            | 0                    |
| Dialysis at discharge (n, %) | 0            | 9 (4.7)             | n.r.             | n.r.                 |
| Creatinine, discharge (mg/dl) | 1.39 (#0.8–2.8) | 1.4                | 1.74             | n.r.                 |
| Creatinine, 6 months (mg/dl) | 0.92 (#0.79–1.6) | n.r.               | n.r.             | n.r.                 |
| Creatinine, 12 months (mg/dl) | 0.91 (#0.8–1.52) | n.r.               | n.r.             | n.r.                 |
| Creatinine, 24 months (mg/dl) | 0.90 (#0.66–1.27) | n.r.               | n.r.             | n.r.                 |
| Platelets, discharge (10⁹/l) | 215 (#114–342) | 266                 | n.r.             | n.r.                 |
| Neurological symptoms, discharge (n, %) | 0       | 5 (2.6)             | n.r.             | 2 (16.6)             |

*Values for the first day of plasmapheresis.

**Seizures, paresis or coma.

LDH, lactate dehydrogenase; n.r., not reported; #, range.

Parameters are expressed as median or as proportion, as appropriate.
Kidney biopsies

A kidney biopsy was performed in 10 of 11 patients at a median of 12 (range 6–22) days after the first dialysis, in order to decide on potential anti-complement therapy. At this time point, 22 (range 8–33) days elapsed from the onset of the diarrhoea (Table 2). At the time of biopsy, six patients required dialysis and the median platelet count was 161 (range 102–285) × 10⁹/l and the median LDH was 239 (range 165–412) U/l.

Light microscopy revealed a median of 12 glomeruli/biopsy, of which, on average, 7% were globally and 13% segmentally sclerosed. With Goldner’s trichrome staining, fragmented erythrocytes could be detected in six (60%) patients (Table 2, Figure 3). Mesangiolysis was detectable in eight (80%) patients. Electron microscopy visualized glomerular endothelial damage manifested as absence of fenestrae in eight (80%) patients and an electrulcent broadening of the subendothelial space in six (60%) biopsies (Table 2, Figure 3). Also in those cases, which showed ongoing TMA by conventional and electron microscopy, only faint staining for complement factors C1q and C3 could be detected by immunohistochemistry (Figure 4). In immunohistochemistry for C4d and C5b-9, no signal was observed, despite the positivity of the corresponding positive controls (Figure 4). In two patients (20%), no signs of acute or past TMA could be detected by light and electron microscopy, despite reduced kidney function (peak creatinine 1.5 and 9.1 mg/dl, respectively) (Table 2, Figure 3).

Analysis revealed moderate to severe tubular epithelial damage manifested as loss of the brush border, epithelial cell flattening and vacuolization, which focally progressed to epithelial necrosis, in all 10 biopsies (Figure 3). Although in the STEC-infected patients the extent of TMA was lower, the tubular damage was significantly higher than in randomly chosen biopsies of patients with TMA with a STEC-unrelated aetiology (Figure 3C; see also supplementary material, Table S1).

In STEC-infected patients, the tubular epithelium showed significantly increased apoptosis with consecutively increased proliferation (Figure 5). In addition, CD44, which is known to be up-regulated by renal tubular epithelial cells in response to various stress stimuli and β-catenin, which is an important regulator of cell–cell adhesion and signalling, were also significantly up- or down-regulated, respectively, in the tubular epithelium of STEC patients as compared to control renal parenchyma (Figure 5). Moreover, the apoptosis and proliferation rates, as well as the up-regulation of CD44, were significantly higher in patients with STEC-induced than with STEC-unrelated TMA (Figure 5).

Impact of Stx2 on human tubular epithelial cells

Humans show expression of Gb3 in all nephron segments (see supplementary material, Figure S4). To analyse the effects of Stx2 on human tubular epithelium in vitro, experiments were performed on the human proximal tubular epithelial cell line HK-2. These cells expressed the Stx2 receptor Gb3 (Figure 6A) and treatment with Stx2 resulted in a significantly increased time- and dose-dependent apoptosis (Figure 6B). Moreover, Stx2 led to an up-regulation of interleukin 8 (IL8), monocyte chemoattractant protein 1 (MCP1) and regulated upon activation normal T cell expressed and presumably secreted (KÄNTES) (Figure 6C). With the exception of MCP1, the co-administration of lipopolysaccharide (LPS) did not further increase the

Table 2. Clinical and histological data.

| Parameter | Median | Range |
|-----------|--------|-------|
| Time from the onset of diarrhoea to biopsy (days) | 22 | 8–33 |
| Time from the first dialysis to biopsy (days) | 12 | 6–22 |
| Patient characteristics | | |
| n | 10 |
| Age (years) | 30 | 22–44 |
| Females (%) | 8 (80) |
| Biochemical parameters at the time of kidney biopsy | | |
| Creatinine (mg/dl) | 2.08 | 1.2–7.44 |
| Platelet count (10⁹/l) | 161 | 102–285 |
| LDH (U/l) | 239 | 165–412 |
| Haemodialysis (n, %) | 6 (60) |
| Histological evaluation | | |
| Tubular epithelial flattening (n, %) | 10 (100) |
| Tubular epithelial vacuolization (n, %) | 10 (100) |
| Tubular intraluminal cell debris (n, %) | 5 (50) |
| Chronic tubular damage and interstitial fibrosis (% area of cortex) | 3 | 0–10 |
| Glomeruli/biopsy | 12 | 6–41 |
| Percentage of segmentally sclerosed glomeruli (%) | 13 | 0–33 |
| Percentage of globally sclerosed glomeruli (%) | 7 | 0–63 |
| Glomerular intracapillary thrombi (n, %) | 4 (40) |
| Glomerular intracapillary fragmentocytes (n, %) | 6 (60) |
| Glomerular intracapillary mononuclear cells (n, %) | 5 (50) |
| Glomerular intracapillary granulocytes (n, %) | 4 (40) |
| Glomerular endothelial swelling (n, %) | 90 (90) |
| Widening of the subendothelial space (n, %) | 6 (60) |
| Loss of endothelial fenestrae (n, %) | 8 (80) |
| Mesangial matrix expansion (n, %) | 6 (60) |
| Mesangiolysis (n, %) | 8 (80) |
| Podocyte swelling (n, %) | 3 (30) |
| Arteriolar endothelial swelling (n, %) | 5 (50) |

Parameters are expressed as median or as proportions, as appropriate.
Figure 3. Legend on the next page.
production of these cytokines (Figure 6C). The production of these cytokines under the influence of Stx2 was also mirrored by an increased infiltration of granulocytes, monocytes/macrophages and T cells in kidney biopsies from STEC-infected patients (Figure 6D). For monocytes/macrophages and T cells, this infiltration was significantly higher in STEC-infected patients than in individuals with STEC-unrelated TMA (Figure 6D), thus suggesting that the observed effects of Stx2 on tubular epithelial cells are not merely a secondary phenomenon of glomerular TMA.

Discussion

Humans express the Stx2 receptor Gb3 not only on renal endothelial but also on tubular cells (see supplementary material, Figure S4). We were intrigued by the idea, also supported by experimental data from other groups, that there might be additional pathophysiological mechanisms independent of glomerular TMA by which Stx2 would cause acute kidney failure in humans [39–43]. In order to dissect direct Stx2-elicited tubulotoxic effects from secondary effects mediated by upstream glomerular TMA, we applied a mouse model of Stx2 toxicity. As shown by others and ourselves, in the kidneys of WT mice, Gb3 expression is limited to collecting ducts but is absent from renal endothelial cells (Figure 1; see also supplementary material, Figures S1, S2 [42–44]). The lack of Gb3 in murine renal endothelial and its pure tubule-specific expression are further supported by the facts that: (a) in mice with Fabry disease (lysosomal storage disease characterized by defective degradation of Gb3), no Gb3 accumulates in renal endothelial cells [45]; and (b) no residual Gb3 is present in murine kidneys when genetically depleting it from tubular cells [46].

The absence of Gb3 from murine renal endothelial cells excluded the possibility that, upon administration of Stx2, potential secondary effects on the tubular epithelium would occur as a result of glomerular TMA. Although glomerular TMA has been reported in Stx2-injected mice by others (with or without co-administering LPS), ultrastructural evidence and appropriate controls have not been provided [38,47,48]. We could not detect any TMA in moribund Stx2-injected WT mice (Figure 1C). This is not surprising, in view of that fact that murine glomerular endothelium did not express Gb3 (Figure 1A; see also supplementary material, Figure S1 [42]). Instead, we found that 36 h after the Stx2-injection, WT mice showed a profound hypotension and hyperkalaemia, which were accompanied by an inverse change of these electrolytes in the urine (Figure 1F), thus indicating initial severe tubular failure. This confirms the previous findings of Wadolkowski et al [39] and Tesh et al [40], who pinpointed acute tubular damage without any TMA in STEC-infected and Stx2-injected mice, respectively. The results are also congruent with previous observations of polyuria in Stx2-injected rats [41] and an increased urine production and apoptosis of the collecting duct epithelium in Stx2-injected mice [42,43].

In order to demonstrate that these tubular changes are causal and do not represent an epiphenomenon (eg from prerenal causes or hormone disturbances due to adrenal or central nervous toxicity), we applied a transgenic mouse model which generated a pure tubular deficiency of Gb3 (Pax8cre/+Ugcgfl/fl), thereby allowing Stx2 to exert its effects on all but tubular epithelial cells. These mice were fully protected from acute renal failure and electrolyte disturbances (Figure 1F), thus providing further evidence for a direct toxicity of Stx2 towards the renal tubular epithelium in vivo. The protection from tubular dysfunction in the Pax8cre/+Ugcgfl/fl mice in turn allowed the development of cerebral purpura at days 4–8 after Stx2 injection, ie at a time point not reached by WT mice because of death due to kidney failure (Figure 2A–C). The cerebral purpura and animal survival were ameliorated by an additional deficiency for Gb3 in the endothelium (Pax8cre/+Tie2cre/+Ugcgfl/fl) (Figure 2D), indicating that Stx2 toxicity towards the brain microcirculatory endothelium and the renal tubular epithelia.
are leading to different organ manifestations of the same disease. Interestingly, Bridgwater et al [49] have described small vessel damage with consecutive haemorrhages in the grey matter of rabbits upon injection of Shigatoxin.

Most studies addressing the effects of Stx2 on human kidneys have been based on analysis of autopsies, which do not allow a differentiation between the prefinal renal damage, post mortem autolysis, potential vascular and glomerular disease-associated tubular damage and direct tubulotoxicity. We documented in 10 living STEC-infected patients, who were biopsied during the acute disease course, that an acute and potentially reversible tubular damage is also a constant finding in humans. Whereas histological signs of recent TMA did not represent a constant finding in these patients, all cases presented with moderate to severe acute tubular damage (Table 2, Figures 3, 5). One might surmise that the acute tubular damage represented a secondary effect of the upstream glomerular TMA. Although the latter was certainly a contributor to acute tubular damage, we provide several lines of evidence for direct Stx2 tubulotoxicity. First, the extent of the acute tubular damage was higher in STEC-infected patients than in individuals with STEC-unrelated TMA, although the extent of TMA was higher in the latter group (Figure 3C). In agreement with a previous report [50] we could show, in an isolated cell culture system in vitro, that tubular epithelia, which express the Stx2 receptor Gb3, undergo apoptosis under the influence of Stx2 (Figure 6A, B). In

© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk
Immunohistochemical findings of the STEC-associated acute tubular damage. Expression of cleaved caspase 3, Ki67, β-catenin and CD44 were studied by immunohistochemistry in STEC-infected patients (n = 10) and compared to normal kidney tissue from tumour nephrectomies (control, n = 8) and to kidney biopsies with TMA due to a STEC-unrelated aetiology (non-STEC, n = 9). The acute tubular damage was associated with a significant increase in apoptosis (visualized by cleaved caspase 3), reactive proliferation (visualized by Ki67) and elevated expression of CD44 in both STEC and non-STEC groups. However, for all three parameters, the increase was significantly higher in the STEC than in the non-STEC group. In the STEC group, apoptosis (arrow) and mitosis (arrowhead) could be seen in tubular epithelial cells; β-catenin was significantly down-regulated in renal tubular epithelium of both STEC and non-STEC patients, to a similar extent; magnification = ×100. In the case of immunohistochemistry for cleaved caspase 3 and Ki67, the number of positive tubular cells was counted and expressed as average cell number/high power field (HPF; ×40 objective, ×10 ocular). For evaluation of the immunohistochemistry for β-catenin and CD44, semiquantitative scoring of the staining intensity of tubular cells in each HPF of the biopsy was performed; in the non-STEC group, individuals >45 years are depicted as squares. Statistical differences were tested by two-tailed Mann–Whitney test; ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001.

In addition, in tubular cells in vitro, Stx2 elicited secretion of cytokines (IL8, MCP1 and RANTES) which could be associated with an increased infiltration of granulocytes, monocytes/macrophages and T cells in the kidneys of patients suffering from a STEC-related, as compared to STEC-unrelated, disease (Figure 6C, D). This finding is supported by previous studies on baboons, which showed an increased production of cytokines (including IL8 and MCP1) in kidneys upon Stx2 injection [14]. Similarly, we could detect that processes such as tubular CD44 up-regulation and β-catenin down-regulation, which were previously implicated in different models of
Stx toxicity [51,52], play also a role in the human disease (Figure 5).

Although the cohort presented here was comparable for most parameters with the eculizumab-treated groups in other studies [25,26] and with immunoadsorption-treated patients [53] (Table 1), a resolution of neurological symptoms and a restoration of kidney function were achieved in all our patients without eculizumab administration. The acute tubular damage and the high regenerative capacity of tubular epithelia probably contributed to the fact that the severely deteriorated kidney function was restored completely. This is also in line with the clinical observation that supportive care and an early volume expansion mitigate Stx-associated kidney failure and shorten the duration of hospitalization [54,55]. Immunohistochemistry did not reveal any presence of the complement factors C5b–9, thus strengthening the notion that persistent complement activation may not play a prominent role. Interestingly, also in a non-human primate model, no increase in the soluble C5b–9 could be found during Stx1- and Stx2-elicited TMA [56]. The lack of a significant complement activation might explain why reports from the 2011 German epidemic [25,26] failed to reveal any benefit of eculizumab treatment. On the other hand, this epidemic differed from past ones by predominantly (88%) affecting adults, while the initial use of eculizumab for STEC-infected patients was reported on three 3 year-old infants [24], which, in contrast to adults, might have a more pronounced expression of the Stx2-receptor on the glomerular endothelium [57].

In summary, we have provided experimental and clinical data that strengthen the hypothesis that acute tubular damage might represent an additional, and until now
underestimated, pathophysiologival mechanism of kid-ney failure after exposure to Stx2. As implicated by the mouse experiments, this tubular damage reflects a primary Stx2 toxicity towards the tubular epithelium. The excellent outcome in all of our 11 patients showed that optimized supportive therapy is likely to suffice for the regeneration of tubular damage and the full recovery of kidney function, and that the treatment of adults, even with severe renal involvement, may not necessarily require complement inhibition.

Acknowledgements

This study was supported by the Deutsche Forschungs-gemeinschaft (DFG; Grant Nos SFB 938 to HJG and SP, and MU845/4-2 to JM) and the Interdisciplinary Centre for Clinical Research (IZKF; Münster Project, Grant No. Müh2/028/10).

Author contributions

SP, HJG and CB designed the research; SP, GF, RJ, JM and NG performed experiments; SP, EG, SB, NO, OJ, IAH, HG and CB collected and analysed the data; and SP, HJG and CB wrote the manuscript.

Abbreviations

CAE, chloracetate esterase; Gb3, globotrihexosylceramide; HUS, haemolytic uraemic syndrome; IL8, interleukin 8; LPS, lipopolysaccharide; MCP1, monocyte chemoattractant protein 1; RANTES, regulated upon leukin 8; LPS, lipopolysaccharide; HUS, haemolytic uraemic syndrome; IL8, interleukin 8; TMA, thrombotic microangiopathy; WT, wild-type.

References

1. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983; 308: 681–685.
2. Karmali MA, Petric M, Lim C, et al. The association between idiopathic haemolytic uraemic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775–782.
3. MMWR. Update: multistate outbreak of Escherichia coli O157:H7 infections from hamburgers – western United States, 1992–1993. MMWR Morb Mortal Wkly Rep 1993; 42: 258–263.
4. Michino H, Araki K, Minami S, et al. Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakaki City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol 1999; 150: 787–796.
5. Thorpe CM. Shiga toxin-producing Escherichia coli infection. Clin Infect Dis 2004; 38: 1298–1303.
6. Trachtman H, Austin C, Lewinski M, et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012; 8: 658–669.
7. Obrig TG. Escherichia coli/Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2011; 2: 2769–2794.
8. Frank C, Werber D, Cramer JP, et al. Epidemiologic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365: 1771–1780.
9. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011; 11: 671–676.
10. Mellmann A, Harmsen D, Cummings CA, et al. Prospective genomic characterization of the German enterohaemorrhagic Escherichia coli O104:H4 outbreak by rapid next-generation sequencing technology. PLoS One 2011; 6: e22751.
11. Rasko DA, Webster DR, Sahl JW, et al. Origins of the E. coli strain causing an outbreak of haemolytic–uremic syndrome in Germany. N Engl J Med 2011; 365: 709–717.
12. Boyd B, Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nepron 1989; 51: 207–210.
13. Lentz EK, Leyva-Illades D, Lee M-S, et al. Differential response of the human renal proximal tubular epithelial cell line HK-2 to Shiga toxin types 1 and 2. Infect Immun 2011; 79: 3527–3540.
14. Stearns-Kurosawa DJ, Oh SY, Cherla RP, et al. Distinct renal pathophysiology and a chemotactic phenotype after enterohaemorrhagic Escherichia coli Shiga toxins in non-human primate models of haemolytic uraemic syndrome. Am J Pathol 2013; 182: 1227–1238.
15. Morigi M, Buelli S, Zanchi C, et al. Shigatoxin-induced Endothelin-1 expression in cultured podocytes autonomically mediates actin remodeling. Am J Pathol 2006 Dec; 169: 1965–1975.
16. Johannes L, Mayor S. Induced domain formation in endocytic invagina-tion, lipid sorting, and scission. Cell 2010; 142: 507–510.
17. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated haemolytic uraemic syndrome: a systematic review, meta-analysis, and meta-regression. J Am Med Assoc 2005; 290: 1360–1370.
18. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet 1998; 352: 1207–1212.
19. Gasser C, Gautier E, Steck A, et al. [Hemolytic–uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenr 1955; 85: 905–909.
20. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073–1086.
21. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233–1243.
22. Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N Engl J Med 2009; 361: 1676–1687.
23. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic–uremic syndrome. N Engl J Med 2009; 360: 542–544.
24. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab for atypical hemolytic–uremic syndrome: an analysis of the German STEC–HUS registry. Nephrol Dial Transpl 2012; 27: 3807–3815.
25. Kielstein JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga toxin-producing E. coli O104:H4 induced haemolytic–uremic syndrome: a case–control study. Br Med J 2012; 345: e4565.
26. Menne J, Nitschke M, Stinchele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case–control study. Br Med J 2012; 345: e4565.
27. Porubsky S, Schmid H, Bonrouhi M, et al. Influence of native and hypochlorite-modified low-density lipoprotein on gene expression in human proximal tubular epithelium. Am J Pathol 2004; 164: 2175–2187.
Table S1. Parameters of the control group with STEC-unrelated TMA

Figure S1. Expression of Gb3 in native and LPS-injected mice

Figure S2. Segment-specific expression of Gb3 in mice

Figure S3. Immunohistochemistry for C3 in Stx2-injected mice

Figure S4. Expression of Gb3 in human kidneys

SUPPLEMENTARY MATERIAL ON THE INTERNET

The following supplementary material may be found in the online version of this article:

Supplementary materials and methods

Figure S1. Expression of Gb3 in native and LPS-injected mice

Figure S2. Segment-specific expression of Gb3 in mice

Figure S3. Immunohistochemistry for C3 in Stx2-injected mice

Figure S4. Expression of Gb3 in human kidneys

Table S1. Parameters of the control group with STEC-unrelated TMA